Primary Endpoint News Today

peddling denial. but you do get that is not the whole story, right? you understand the vaccine is not a cure-all. it wont get us out of the pandemic, not anytime soon. there are so many out there, i hear you on the radio, i see you on social media, i get your responses to the show. bidens doing a good job, take the win, why do you keep saying the situation is so dire? because it is. vaccine, biden, not enough. hes not trump. hes not going to tell you hes one move away and only he can f...

Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.

/PRNewswire/ -- Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal...

– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated –

Antibody persistence of a single-doselive-attenuated chikungunya virus vaccine in adults. World Vaccine Congress, Washington 03-Apr-2024 ...

The company reported that it met its primary endpoint in a study for its non-opioid pain drug.

Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second half of 2024 In Japan, China and most countries in Europe cyclobenzaprine is a New Chemical Entity CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of de...

-Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -

As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued…

Primary endpoint met: deucrictibant significantly reduced attack rate The primary endpoint of the CHAPTER-1 study measured the time-normalized number of investigator-confirmed HAE attacks during the treatment period. The monthly attack rate was reduced by 84.5% (p=0.0008) compared to placebo in participants who received 40 mg/day of deucrictibant. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to place